Literature DB >> 17605730

Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection.

C R Sims1, K Thompson, R F Chemaly, E J Shpall, R E Champlin, A Safdar.   

Abstract

We present a case of serious treatment-refractory acyclovir- and foscarnet-resistant herpes simplex virus (HSV) type-1 orolingual infection that responded to oral cidofovir rinses after failure of acyclovir and foscarnet therapy. The use of 3% cidofovir in a saline rinse for refractory mucosal HSV infection appears promising but needs prospective evaluation.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17605730     DOI： 10.1111/j.1399-3062.2007.00261.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN： 1398-2273            Impact factor:   2.228


  3 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.

Authors:  Joel B Epstein; Sara Gharapetian; Ali R Rejali; Rachel Zabner; Michael Lill; Dimitrios Tzachanis
Journal:  Support Care Cancer       Date:  2016-05-10       Impact factor: 3.603

Review 3.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.